# Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

> **NCT00588770** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 403 (actual)

## Conditions studied

- Neck Squamous Cell Carcinoma of Unknown Primary
- Recurrent Hypopharyngeal Squamous Cell Carcinoma
- Recurrent Laryngeal Squamous Cell Carcinoma
- Recurrent Laryngeal Verrucous Carcinoma
- Recurrent Lip and Oral Cavity Squamous Cell Carcinoma
- Recurrent Neck Squamous Cell Carcinoma of Unknown Primary
- Recurrent Oral Cavity Verrucous Carcinoma
- Recurrent Oropharyngeal Squamous Cell Carcinoma
- Recurrent Salivary Gland Carcinoma
- Recurrent Sinonasal Squamous Cell Carcinoma
- Salivary Gland Squamous Cell Carcinoma
- Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7
- Stage IV Major Salivary Gland Cancer AJCC v7
- Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7
- Stage IVA Laryngeal Verrucous Carcinoma AJCC v7
- Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
- Stage IVA Major Salivary Gland Cancer AJCC v7
- Stage IVA Oral Cavity Cancer AJCC v6 and v7
- Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7
- Stage IVA Sinonasal Squamous Cell Carcinoma AJCC v7
- Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7
- Stage IVB Laryngeal Verrucous Carcinoma AJCC v7
- Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
- Stage IVB Major Salivary Gland Cancer AJCC v7
- Stage IVB Oral Cavity Cancer AJCC v6 and v7
- Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7
- Stage IVB Sinonasal Squamous Cell Carcinoma AJCC v7
- Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7
- Stage IVC Laryngeal Verrucous Carcinoma AJCC v7
- Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7
- Stage IVC Major Salivary Gland Cancer AJCC v7
- Stage IVC Oral Cavity Cancer AJCC v6 and v7
- Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7
- Stage IVC Sinonasal Squamous Cell Carcinoma AJCC v7
- Tongue Carcinoma

## Interventions

- **BIOLOGICAL:** Bevacizumab
- **DRUG:** Carboplatin
- **DRUG:** Cisplatin
- **DRUG:** Docetaxel
- **DRUG:** Fluorouracil
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT00588770
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2008-08-08
- **Primary completion:** 2018-06-05
- **Final completion:** 2027-02-20
- **Target enrollment:** 403 (ACTUAL)
- **Last updated:** 2026-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00588770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00588770, "Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00588770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*